Media headlines about Bioamber (NYSE:BIOA) have trended somewhat positive recently, according to AlphaOne Sentiment. The research firm, a division of Accern, identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioamber earned a media sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also gave news articles about the biotechnology company an impact score of 66 out of 100, indicating that recent press coverage is likely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted AlphaOne Sentiment’s scoring:
- New York Cosmos to Ring The Nasdaq Stock Market Closing Bell (econotimes.com)
- BIOA ALERT: Rosen Law Firm Reminds BioAmber Inc. Investors of Important Deadline in First Filed Class Action – BIOA (forextv.com)
- BIOA ALERT: Rosen Law Firm Reminds BioAmber Inc. Investors of Important Deadline in First Filed Class Action – BIOA (finance.yahoo.com)
- BIOA EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of BioAmber Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 – BIOA (finance.yahoo.com)
- BIOAMBER INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm (4-traders.com)
BIOA has been the topic of several research reports. Cowen and Company initiated coverage on shares of Bioamber in a research report on Wednesday, April 12th. They set a “market perform” rating and a $2.50 price objective on the stock. AltaCorp Capital restated an “outperform” rating on shares of Bioamber in a research report on Monday, January 30th. Finally, Zacks Investment Research cut shares of Bioamber from a “buy” rating to a “hold” rating in a research report on Tuesday, January 3rd.
Bioamber (NYSE:BIOA) traded up 1.41% during trading on Thursday, hitting $2.16. 143,056 shares of the company traded hands. The stock’s market capitalization is $75.27 million. The company’s 50 day moving average is $2.63 and its 200-day moving average is $4.12. Bioamber has a 52 week low of $2.00 and a 52 week high of $6.50.
Bioamber (NYSE:BIOA) last posted its quarterly earnings data on Thursday, March 16th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.12. Bioamber had a negative net margin of 227.35% and a negative return on equity of 63.08%. The firm had revenue of $0.63 million for the quarter, compared to the consensus estimate of $3.77 million. Analysts predict that Bioamber will post ($0.45) earnings per share for the current year.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065252/bioamber-bioa-earns-media-sentiment-rating-of-0-12.html
Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.